The Attgeno organisation

The Attgeno team contains the synthesis of world leading nitric oxide experts and individuals with a record of successful commercialization of discoveries in the fields of nitric oxide biology and chronic pulmonary hypertension. 

  • The late Professor Lars E. Gustafsson and Attgeno’s chairman of the board, Assistant Professor Magnus Persson discovered exhaled nitric oxide (FeNO) and founded the company Aerocrine that developed and commercialized a diagnostic instrument (NIOX™) to monitor asthma treatment. The Swedish asthma diagnostic company Aerocrine was acquired by biotech Circassia for EUR 171 million in June 2015. 

  • The head of Attgeno’s scientific advisory board Professor Claes Frostell was, together with the late professor Warren Zapol, instrumental in the development of inhaled nitric oxide as a treatment for premature infants with respiratory insufficiency. FDA approved inhalation gas INOmax™ for the treatment of hypoxic respiratory failure of the term and near-term newborn in 1993.

  • Attgeno’s chairman of the board Magnus Persson and former Attgeno board member Elisabet Lindberg have been contributing parts in building Actelion Ltd, a billion-Euro company with blockbuster drugs for the treatment of chronic pulmonary hypertension. The acquisition of Actelion by Johnson & Johnson for a total purchase price of approximately EUR 24 billion in cash was announced in June 2017

Board of Directors
Management Team